CORT — Corcept Therapeutics Incorporated

Summary of Corcept Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $207.6 million for Q3 2025, up from $182.5 million in Q3 2024.
• Net Income: $19.7 million, significantly down from $47.2 million in the prior year.
• Cash and Investments: $524 million as of September 30, 2025, reflecting a $50 million stock repurchase.
• Revised Revenue Guidance: Adjusted to $800 million to $850 million for 2025.

2. Strategic Updates and Business Highlights

• Hypercortisolism Business Growth: Record shipments of Korlym, with a 42.5% increase in tablets shipped compared to last year. The prescriber base has expanded significantly.
• Pharmacy Transition: Transitioning to a new pharmacy (Curant) due to capacity issues with the previous vendor. A second specialty pharmacy is planned for January 2026.
• Clinical Developments:
  • NDA for relacorilant for hypercortisolism has a PDUFA date of December 30, 2025.
  • NDA for relacorilant in platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026.
  • Upcoming results expected from multiple trials, including MOMENTUM and ROSELLA.
• Oncology Expansion: Plans to broaden oncology studies beyond ovarian cancer, including trials for endometrial and pancreatic cancers.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipate continued growth in the hypercortisolism market, with expectations that relacorilant could generate $3 billion to $5 billion in annual revenue within 3-5 years.
• Q4 Revenue Expectations: Projected revenue growth of approximately 28% from Q3 to Q4, aiming for around $265 million in Q4 sales.
• R&D and SG&A Spending: R&D expenditures expected to remain stable, while SG&A expenses will increase to support product launches and clinical studies.

4. Bad News, Challenges, or Points of Concern

• Declining Net Income: A notable decrease in net income compared to the previous year raises concerns about profitability amidst increasing revenues.
• Capacity Constraints: Ongoing capacity issues with the previous pharmacy vendor may affect short-term growth, although the new pharmacy is expected to alleviate these issues.
• Patent Litigation: Uncertainty surrounding the ongoing patent litigation with Teva Pharmaceuticals, which could impact market dynamics if not resolved favorably.

5. Notable Q&A Insights

• Patient Base: Approximately 3,250 paying patients on Korlym as of the end of Q3.
• Capacity of New Pharmacy: Curant is fully operational and expected to handle increased volume effectively.
• Authorized Generic Sales: Over 70% of sales now come from the authorized generic, with a projected increase to around 75% by year-end.
• Regulatory Insights: The company had both mid-cycle and late-cycle reviews for relacorilant, with confidence in meeting the FDA's target date for approval.

Overall, Corcept Therapeutics is positioned for growth with significant upcoming product launches and a strong pipeline, despite facing challenges related to profitability and capacity constraints.